Literature DB >> 21519233

Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with chronic kidney disease.

Manal F Elshamaa1, Samar Sabry, Ahmed Badr, Mostafa El-Ahmady, Eman A Elghoroury, Eman H Thabet, Dina Kandil, Solaf Kamel.   

Abstract

Nitric oxide production is reduced in renal disease, partially due to decreased endothelial nitric oxide production. Evidence indicates that nitric oxide deficiency contributes to cardiovascular events and progression of kidney damage. A polymorphism in intron 4 of the endothelial constitutive nitric oxide synthase (ecNOS) gene is a candidate gene in cardiovascular and renal diseases. We investigated a potential involvement of this polymorphism in chronic renal failure. A case-control study involved 78 children with chronic kidney disease (CKD) and 30 healthy controls. All participants were genotyped for the ecNOS4 polymorphism by the polymerase chain reaction (PCR). Dialyzed (maintenance hemodialysis) and conservative treatment children had significantly higher frequency of the aa genotype and ecNOS4a allele (P<0.05) compared with controls. The combined genotype aa+ab vs. bb comparison validated that a allele is a high-risk allele for end-stage renal disease (ESRD) (P<0.05). Serum nitric oxide level was found to be lower in carriers of the ecNOS 4a allele than in noncarriers (100.29±27.32 vs. 152.73±60.39 μmol/l, P=0.04). Interestingly, 85.95% of the ecNOS 4a allele ESRD patients were found hypertensive in comparison to the 60.67% patients of non noncarriers (bb genotype) (P=0.04). Also, 35.90% of the ecNOS 4a allele ESRD patients were found to have cardiovascular disease in comparison to the 5.13% patients of noncarriers (bb genotype) (P=0.01). On multiple linear regression analysis, a allele was independently associated with hypertension (P=0.03). There was a significantly higher frequency of the ecNOS4a allele carriers among CKD children, both on MHD and conservative treatment than in controls. This suggests that the ecNOS gene polymorphism may be associated with an increased risk of chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519233     DOI: 10.1097/MBC.0b013e328346ef71

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Klotho G-395A gene polymorphism: impact on progression of end-stage renal disease and development of cardiovascular complications in children on dialysis.

Authors:  Eman A Elghoroury; Fatina I Fadel; Manal F Elshamaa; Dina Kandil; Doaa M Salah; Marwa M El-Sonbaty; Hebatallah Farouk; Mona Raafat; Soha Nasr
Journal:  Pediatr Nephrol       Date:  2018-01-08       Impact factor: 3.714

2.  Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease.

Authors:  Ramprasad Elumalai; Soundararajan Periasamy; Gnanasambandan Ramanathan; Bhaskar Vks Lakkakula
Journal:  J Renal Inj Prev       Date:  2014-07-01

Review 3.  Pharmacogenomics of sickle cell disease: steps toward personalized medicine.

Authors:  Marium Husain; Amber D Hartman; Payal Desai
Journal:  Pharmgenomics Pers Med       Date:  2017-10-19

4.  Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis.

Authors:  Atma Gunawan; Jonny Karunia Fajar; Fredo Tamara; Aditya Indra Mahendra; Muhammad Ilmawan; Yeni Purnamasari; Dessy Aprilia Kartini; Eden Suryoiman Winoto; Efriko Septananda Saifillah; Dewi Sri Wulandari; Pratista Adi Krisna; Ema Dianita Mayasari; Tri Wahyudi Iman Dantara; Ramadi Satryo Wicaksono; Djoko Wahono Soeatmadji
Journal:  F1000Res       Date:  2020-04-09

5.  Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.

Authors:  Daniel Stehle; Min Ze Xu; Tibor Schomber; Michael G Hahn; Frank Schweda; Susanne Feil; Jan R Kraehling; Frank Eitner; Andreas Patzak; Peter Sandner; Robert Feil; Agnès Bénardeau
Journal:  Br J Pharmacol       Date:  2021-07-03       Impact factor: 9.473

6.  An African perspective on the genetic risk of chronic kidney disease: a systematic review.

Authors:  Cindy George; Yandiswa Y Yako; Ikechi G Okpechi; Tandi E Matsha; Francois J Kaze Folefack; Andre P Kengne
Journal:  BMC Med Genet       Date:  2018-10-19       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.